Sign in

Shirley Tan

Research Analyst at Barclays PLC

Shirley Tan is currently an analyst at Barclays PLC, where she specializes in financial and sector analysis. Publicly available data does not confirm her exact current title, provide a list of specific companies she covers, or disclose her detailed performance metrics or professional investment rankings. Information about her career timeline, previous firms, and professional credentials, including licenses or FINRA registration, could not be verified across accessible sources. Due to the absence of a valid LinkedIn profile and third-party performance data, comprehensive professional achievements or notable recognitions are not documented for Shirley Tan at Barclays.

Shirley Tan's questions to NOVARTIS (NVS) leadership

Question · Q3 2025

Shirley Tan asked about Pluvicto's launch curve, expected inflection in Q4 and next year, peak sales ambition, and progress in tackling commercialization challenges like reimbursement and referral networks.

Answer

CEO Vasant Narasimhan stated that Pluvicto is on the steep part of its launch curve with strong Q3 growth, expecting solid Q4 growth despite holiday slowdowns. He reaffirmed the $5 billion peak sales ambition, driven by the pre-taxane launch and future HSPC indication. He noted successful tackling of structural challenges, with over 700 prescribing clinics and high patient access, and increased comfort with prefilled syringes, building a strong foundation for the radioligand therapy platform.

Ask follow-up questions

Fintool

Fintool can predict NOVARTIS logo NVS's earnings beat/miss a week before the call

Question · Q3 2025

Shirley Tan asked about Pluvicto's launch curve, expected inflection in Q4 and next year, peak sales ambition, and progress in tackling commercialization challenges like reimbursement and referral networks.

Answer

Vasant Narasimhan, CEO of Novartis, stated that Pluvicto is on the steep part of its launch curve with strong Q3 growth, expecting solid Q4 growth despite holiday slowdowns. He reaffirmed the $5 billion peak sales potential, driven by the pre-taxane launch and future HSPC indication. He noted successful tackling of structural challenges, with over 700 prescribing clinics and high patient access, supported by the prefilled syringe rollout.

Ask follow-up questions

Fintool

Fintool can write a report on NOVARTIS logo NVS's next earnings in your company's style and formatting